

George DJ, et al. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the nonrandomized, open-label phase 3b/4 CheckMate 920 trial

<b>Table of contents</b>	<b>Page</b>
<b>Table S1</b> Cumulative dose and relative dose intensity summary	<b>2</b>

This supplementary material has been provided by the authors to give readers additional information about their work

**Table S1** Cumulative dose and relative dose intensity summary

	<b>NIVO (N = 106)</b>	<b>IPI (N = 106)</b>
<b>Relative dose intensity, n (%)<sup>a</sup></b>		
≥110%	0	1 (0.9)
90% to <110%	92 (86.8)	91 (85.8)
70% to <90%	14 (13.2)	14 (13.2)
<b>No. of doses received, n (%)</b>		
1	11 (10.4)	21 (19.8)
2	9 (8.5)	22 (20.8)
3	20 (18.9)	15 (14.2)
4	2 (1.9)	5 (4.7)
>4	64 (60.4)	43 (40.6)

<sup>a</sup>Relative dose intensities for NIVO and IPI were calculated as follows: cumulative dose (mg) × 100/ total expected dose (mg); cumulative dose (mg) was defined as the sum of the doses (mg) administered to a patient during the treatment period.